NasdaqGM - Delayed Quote • USD
Eagle Pharmaceuticals, Inc. (EGRX)
At close: April 23 at 4:00 PM EDT
After hours: April 23 at 5:27 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2023) | Next Qtr. (Dec 2023) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | 1.12 | 1.1 | -- | -- |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2023) | Next Qtr. (Dec 2023) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | 62.83M | 64.51M | 258.29M | 224.81M |
| Low Estimate | 62.83M | 64.51M | 258.29M | 224.81M |
| High Estimate | 62.83M | 64.51M | 258.29M | 224.81M |
| Year Ago Sales | 62.08M | 60.7M | 316.61M | 258.29M |
| Sales Growth (year/est) | 1.20% | 6.30% | -18.40% | -13.00% |
Earnings History
| CURRENCY IN USD | 9/30/2022 | 12/31/2022 | 3/31/2023 | 6/30/2023 |
|---|---|---|---|---|
| EPS Est. | 0.91 | 0.83 | 1.05 | 1.05 |
| EPS Actual | 1.12 | 1.1 | 1.26 | 1.18 |
| Difference | 0.21 | 0.27 | 0.21 | 0.13 |
| Surprise % | 23.10% | 32.50% | 20.00% | 12.40% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2023) | Next Qtr. (Dec 2023) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 1.09 | 1.07 | 4.69 | 3.48 |
| 30 Days Ago | 1.09 | 1.07 | 4.69 | 3.48 |
| 60 Days Ago | 1.09 | 1.07 | 4.69 | 3.48 |
| 90 Days Ago | 1.09 | 1.07 | 4.69 | 3.48 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2023) | Next Qtr. (Dec 2023) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | -- | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | EGRX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 0.40% |
| Next Qtr. | -- | -- | -- | 9.90% |
| Current Year | -- | -- | -- | 4.30% |
| Next Year | -- | -- | -- | 13.40% |
| Next 5 Years (per annum) | 2.70% | -- | -- | 11.09% |
| Past 5 Years (per annum) | 11.34% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Downgrade | Piper Sandler: Neutral to Underweight | 8/9/2023 |
| Maintains | Cantor Fitzgerald: Neutral | 3/2/2020 |
| Maintains | Mizuho: Neutral to Neutral | 3/22/2019 |
| Downgrade | Piper Sandler: Overweight to Neutral | 10/31/2018 |
| Maintains | Cantor Fitzgerald: Overweight to Overweight | 9/21/2018 |
| Initiated | Cantor Fitzgerald: Overweight | 6/12/2018 |
Related Tickers
ETON Eton Pharmaceuticals, Inc.
3.2800
+0.92%
EBS Emergent BioSolutions Inc.
2.2900
+6.02%
ALKS Alkermes plc
24.26
+0.79%
LFCR Lifecore Biomedical, Inc.
6.45
+2.54%
IRWD Ironwood Pharmaceuticals, Inc.
8.31
+3.10%
AMRX Amneal Pharmaceuticals, Inc.
5.40
+0.56%
HROW Harrow, Inc.
10.32
-2.64%
CPIX Cumberland Pharmaceuticals Inc.
1.6400
+1.23%
PCRX Pacira BioSciences, Inc.
26.81
+2.72%
FAGR.BR Fagron NV
17.86
+0.11%